Oncology Pharma Licensor and Co-Development Partner, Kalos Therapeutics, Announces Progress in Covid-19 Preventative & Therap
April 21 2020 - 4:33PM
InvestorsHub NewsWire
Oncology Pharma Licensor and Co-Development Partner, Kalos
Therapeutics, Announces Progress in Covid-19 Preventative &
Therapeutic Approaches
Oncology Pharma Inc. (OTCPK:ONPH)
is pleased to announce further information from it's Licensor,
Kalos Therapeutics "Kalos"
PHOENIX, AZ -- April 21, 2020 -- InvestorsHub NewsWire
-- Kalos Therapeutics announced its latest progress
in its efforts to discover and develop a novel multi-drug cocktail
of investigational peptide KTH-222 and immune-stimulating agents
that can be administered as prophylaxis before exposure to the
SARS-CoV-2 virus or as a treatment for immune-compromised cancer
patients already infected. The key here will be an opportunity for
treating asymptomatic patients. Kalos has identified numerous
immune-stimulating agents and will target two based on safety and
efficacy, as well as other desirable attributes, to begin
development.
George Colberg, CEO of Kalos Therapeutics, said, "Through our
network of patients and key opinion leaders we are learning that
many patients, that may have a weak immune-system, are reluctant to
venture out for the continuation of therapies. Using a multi-drug
approach to protect the most vulnerable cancer patients with
cardiovascular issues and/or weakened immune-system is an urgent
unmet need that is a priority for Kalos Therapeutics." He added,
"KTH-222 as a monotherapy and/or in combination with FDA- approved
anti-viral therapies or as compassionate drugs will potentially
benefit cancer patients at risk including those not yet
demonstrating symptoms."
In order to meet the pressing public health need, Kalos is in
discussion with BARDA for funding opportunities through BAA and
Corona Watch Meeting, collaborative opportunities, to hone
strategies, and align with Government priorities to address this
unmet need.
Oncology Pharma and Kalos Therapeutics were recently mentioned
in the BioWorld website:
https://www.bioworld.com/articles/434359-week-in-review-for-april-6-10-2020
ABOUT ONCOLOGY PHARMA, INC.
Oncology Pharma, Inc. (OTCPK:ONPH)
(the "Company") is a pioneering oncology company dedicated to
developing, manufacturing, and commercializing therapeutics. The
Company has entered into Letter of Intents with Kalos Therapeutics
for its lead anticancer drug, KTH-222, Diagnomics (a CLIA and CAP
accredited molecular diagnostic Lab), NanoSmart Pharmaceuticals for
its targeted drug delivery platform and a licensing agreement with
Ribera Solutions for its Connect2Med clinical trial app
platform.
ABOUT KALOS THERAPEUTICS, INC.
Kalos is pursuing a multi-phase strategy to reorient today's
therapeutic approach to cancer patients while driving changes to
transform therapeutic approaches for unmet and rare medical
conditions. Kalos has a lead compound KTH 222, which is more
promising than "standard of care" drugs with difficult to treat
tumors.
Kalos is devoted to treating the unmet needs of people living
with incurable diseases while doing so with less toxic and
debilitating side effects commonly associated with chemotherapies.
Kalos believes that by leveraging nature and all of the body's
mechanisms, they have created new, safer approaches to cancer and
diseases that affect the eye as well. Kalos has several
applications for animal health based on both its eight amino acid
and a 15 amino acid drug KTV-111. Kalos aims to treat dangerous and
debilitating diseases and improve the quality of life for the
patient and their families.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships; and, costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may include onerous terms; unexpected costs and
operating deficits, and lower than expected sales and revenues;
uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition;
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the Company's technology;
management of growth; and, other risks and uncertainties. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038 Fax: 415-946-8801
email: info@oncology-pharma.com
oncology-pharma.com
SOURCE: Oncology Pharma Inc.
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Apr 2023 to Apr 2024